Research programme: cardiovascular disease therapeutics - Biostar Pharmaceuticals/Northwest University

Drug Profile

Research programme: cardiovascular disease therapeutics - Biostar Pharmaceuticals/Northwest University

Latest Information Update: 28 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioStar Pharmaceuticals; Northwest University
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cardiovascular disorders

Most Recent Events

  • 08 Jan 2015 Northwest University has patent protection for Danshensu Yibingzhi in China
  • 08 Jan 2015 Department of Education and Finance, Shaanxi Province, China approved Danshensu Yibingzhi for further industrial and commercial development
  • 29 Dec 2014 Biostar Pharmaceuticals and University of Northwest, China agree to co-develop Danshensu Yibingzhi for Cardiovascular disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top